Cagrilintide
Cagrilintide (AM833 / NNC0174-0833 / NN9838), a long-acting acylated amylin analogue [PMID 34288673; ClinicalTrials.gov orgStudyIdInfo NN9838-4942]
Clinical trials are ongoing or recently completed. Final approval has not been granted.
An investigational once-weekly injection that mimics amylin (a natural hormone your body uses to control appetite), being developed for weight loss and type 2 diabetes. Clinical trials show 10-12% body weight loss on its own, and up to 23% when combined with semaglutide.
This entry is a cited research summary, not an established treatment reference. Dosing language is included as source context, not as medical instruction.
Cagrilintide has substantial clinical evidence but is not FDA-approved.
Clinical trials are ongoing or recently completed. Final approval has not been granted.
Safety Summary
In Phase 2 NCT03856047: nausea 20-47% cagrilintide versus 18% placebo; constipation 8-21% versus 7%; diarrhea 7-18% versus 9%; vomiting 5-9% versus 3%; injection-site reactions 4-12% versus 0% [NCT03856047; PMID 34798060]. In Phase 2 T2D trial: mostly mild-moderate GI events; no level 2 or 3 hypoglycemia reported [PMID 37364590]. REDEFINE 1: GI events 79.6% CagriSema versus 39.9% placebo, mainly transient and mild-moderate [PMID 40544433]. REDEFINE 2: GI events 72.5% CagriSema versus 34.4% placebo [PMID 40544432]. Discontinuation due to AEs 6-8.4% in Phase 3. Hypotension reported in 1.8% CagriSema versus 0.4% placebo in REDEFINE 1 BP analysis [PMID 41328546]. Meta-analysis of 4 RCTs confirmed GI AEs more frequent with CagriSema (RR 1.32) [PMID 41759565].
Clinical check-in
If real-world use or exposure is being considered, review potential interactions, contraindications, and monitoring needs with a licensed clinician rather than relying on summary copy alone.
Cited sources
Every claim on this page links to one of the 10 sources below. Identifiers are PubMed (PMID), ClinicalTrials.gov (NCT), or DOI; click through to the source of record before acting on a claim.
- 1PMID 34288673PubMed
- 2PMID 33894838PubMed
- 3PMID 34798060PubMed
- 4PMID 37364590PubMed
- 5PMID 39279639PubMed
- 6PMID 40544433PubMed
- 7PMID 40544432PubMed
- 8PMID 41328546PubMed
- 9PMID 41759565PubMed
- 10PMID 41747885PubMed